Journal Article |
| Batth, IS., Yun, H., Meng, P., Osmulski, P., Huang, TH., Bedolla, R., Reddick, RE., Kumar AP. Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer Oncotarget 2016 Jan;.
|
| Hambright HG, Meng, P, Kumar AP and Ghosh R. Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget (in press) Oncotarget 2015 Jan;.
|
| Yun, HY., Xie, J., Olumi, AF., Ghosh, R., Kumar AP. Activation of AKR1C1/ERB induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity Oncotarget 2015 Jan;.
|
| Swanson, GP., Jones WE., Ha, CS., Jenkins, CA., Kumar AP and Basler, J. Tolerances of Phellodendron amurense bark extract (Nexrutine) in human prostate cancer patients. Phytotherapy Research doi: 10.1002/ptr. 5221. [Epub ahead of print] PMID:25205619 Phytotherapy Research 2015 Jan;.
|
| Kumar AP. Palmatine suppresses rpS6/NFκB/FLIP to inhibit growth and invasion in androgen independent prostate cancer cells Molecular Carcinogenesis 2014 Jan;.
|
| Gong, JJ., Xie, J., Bedolla, R., Rivas, P., Chakravarthy, D. Freeman, JW., Reddick, R., Kopetz, S., Peterson, A., Wang, H., Fischer, SM and Kumar AP. Combined targeting of Stat3/NFkB/Cox-2/EP4 for effective management of pancreatic cancer Clinical Cancer Research (in press;doi:10.1158/1078-0432.CCR-13-1664);Selected as on of the highlights of the issue 2014 Jan;.
|
| Kumar AP. Combined targeting of Stat3/NF B/Cox-2/EP4 for effective management of pancreatic cancer Clinical Cancer Research 2014 Jan;20.
|
| Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP AND Ghosh R. NQO1 suppresses NF-kB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis Cancer Research 2014 Jan;74(5644):5644-5655.
|
| Chen C-L, Mahalingam D, Osmulski PA, Jadhav RR, Wang C-M, Leach RJ, Weitman SD, Kumar P, Sun L-Z, Gaczynska ME, Thompson J, Huang TH. Single-cell Analysis of Circulating Tumor Cells Identifies Cumulative Expression Patterns of EMT-related Genes in Metastatic Prostate Cancer The Prostate 2013 Jan;73:813-826.
|
| Li, G, Rivas, P, Bedolla, R, Thapa, D, Reddick RL, Ghosh R, Kumar P. Dietary Resveratrol Prevents Development of High-Grade Prostatic Intraepithelial Neoplastic Lesions: Involvement of SIRT1/S6K Axis Cancer Prevention Research 2012 Jan;.
|
| Bedolla RG, Gong J, Prihoda TJ, Yeh IT, Thompson IM, Ghosh R, Kumar AP. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence PLOS ONE 2012 Jan;7(9).
|
Dissertation/Thesis |
| Divya Chakravarthy. Palmatine in pancreatic stellate cell and cancer cell interaction 2015. |
| Izhar Singh Batth. New roles for RON in prostate cancer 2014. |
| Jingjing Gong. NFKB/STAT3/COX-2 Signaling axis: Novel target for pancreatic cancer 2013. |
Abstract |
| Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock, Daniel C. Chan, Rita Ghosh and Addanki P. Kumar. Downregulation of ribosomal protein rpS6 overcomes radioresistance in prostate cancer; 2015 Apr. (Proceedings of American Association for Cancer Research).
|
| Amanda R. Muoz, James W. Freeman, & Addanki P. Kumar. Elucidating the mechanism of the STAT3/NF-?B/EP4 signaling axis in pancreatic cancer; 2014 Nov. (16th Annual South Padre Conference on Advances in Cell Signaling, Cancer Prevention).
|
| Yun, HY., Xie, J., Batth, IS., Li, R., Ghosh, R., Kumar, AP. ER-β/Sp/NFκB/FLIP axis: Potential therapeutic target in prostate cancer; 2014 Nov. (Greehey CCRI 10th Anniversary Symposium, San Antonio).
|
| Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock,Rita Ghosh and Addanki P. Kumar. Nexrutine modulates PI3K/mTOR and NF?B signaling to target radioresistance in prostate cancer; 2014 Nov. (16th Annual South Padre Conference on Advances in Cell Signaling, Cancer Prevention and Therapy).
|
| Yun, HY., Xie, J., Batth, IS., Li, R., Ghosh, R., Kumar. Potential therapeutic target in prostate cancer; 2014 Oct. (21th Annual Graduate Student Symposium, San Antonio).
|
| Yun, HY., Xie, J., Batth, IS., Li, R., Ghosh, R., Kumar. ER-β/Sp/NFκB/FLIP axis: Potential therapeutic target in prostate cancer; 2014 Oct. (16th Annual South Padre Conference on advances in cell signaling cancer prevention and therapy, South Padre Island).
|
| Divya Chakravarthy, Carolina B Livi, Jingjing Gong, Robert R Reddick, Rosa F Hwang, Addanki P Kumar. SPHK1-GLI-COL1A1 axis contributes to pancreatic stellate and cancer cell crosstalk: potential therapeutic avenue; 2014 Jul. (Aspen Cancer Conference).
|
| Batth, I., Gong, J., Kumar, AP. Novel interaction between FLIP/DAPK: role for RON in androgen-independent prostate cancer; 2014 May. (Cellular and Structural Biology Retreat, San Antonio).
|
| Batth, I., Meng, P., Bedolla, R., Reddick, RE, Kumar, AP. RON-mediated hijacking of AR signaling in androgen-independent prostate cancer; 2014 May. (Cellular and Structural Biology Retreat, San Antonio).
|
| Chakravarthy, D., Gong, J., Reddick, R., Hwang, FR., Kumar, AP. Targeting desmoplasia in pancreatic cancer; 2014 May. (Cellular and Structural Biology Retreat).
|
| Batth, I., Meng, P., Bedolla, R., Reddick, RE., Kumar, AP. RON-mediated hijacking of AR signaling in androgen-independent prostate cancer; 2014 Apr. (105th American Association for Cancer Research Annual Meeting, San Diego).
|
| Amanda R. Muoz, James W. Freeman, & Addanki P. Kumar. Elucidating the mechanism of the STAT3/NF-κB/EP4 signaling axis in pancreatic cancer; 2014 Apr. (16th Annual South Padre Conference on Advances in Cell Signaling, Cancer Prevention).
|
| Amanda R. Muoz, Jingjing Gong, Divya Chakravarthy, Daniel E. Chan, James W. Freeman, Rita Ghosh, and Addanki P. Kumar. Targeting the Stat3/NF-κB/EP4 signaling axis through combination treatment with Nexrutine and Gemcitabine for pancreatic cancer (AACR Pancreatic Cancer: Innovations in Research and Treatment); 2014 Jan.
|
| Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock,
Rita Ghosh and Addanki P. Kumar. Nexrutine modulates PI3K/mTOR and NF?B signaling to target radioresistance in prostate cancer; 2014 Jan. (Pharmacology symposium 2014).
|
| Amanda R Munoz, Jingjing Gong, Divya Chakravarthy, Daniel E Chan, James W Freeman, Rita Ghosh, and Addanki P Kumar. Targeting the Stat3/NF-κB/EP4 signaling axis through combination treatment with Nexrutine and Gemcitabine for pancreatic cancer; 2014 Jan. (AACRPancreatic Cancer: Innovations in Research and Treatment, New Orleans, LA,).
|
| Divya Chakravarthy, Jingjing Gong, Rosa F Hwang, and Addanki P Kumar. Targeting desmoplasia in pancreatic cancer; 2014 Jan. (Cellular and Structural Biology Retreat, San Antonio).
|
| Batth IS, Gong J, Kumar, Ph.D. AP. Novel interaction between FLIP/DAPK: role for RON in androgen-independent prostate cancer; 2013 Apr. (American Association for Cancer Research 104th Annual Meeting, Washington, DC).
|
| Batth IS, Gong J, Kumar, Ph.D. AP. RON Kinase Propagates Prostate Tumorigenesis through Interations with AR and FLIP; 2012 Nov. (Advances in Cell Signaling, Cancer Prevention & Therapy 13th Annual Meeting, South Padre Island, Tx).
|
| Gong J, Xie J, Batth IS, Freeman JW, Kumar, Ph.D. AP. Disruption of NFB/Stat3 interaction as a potential therapeutic avenue for pancreatic cancer management; 2012 Jun. (Pancreatic Cancer: Progress and Challenges, Lake Tahow, NV).
|
| Batth IS, Gong J, Bedolla RG, Weintraub ST, Kumar, Ph.D. AP. 2-Methoxyestradiol targets RON kinase and FLIP to inhibit epithelial-mesenchymal transition in Prostate Cancer; 2012 Apr. (American Association for Cancer Research 103rd Annual Meeting, Chicago, IL).
|
| Jingjing Gong, James W Freeman, Kumar, Ph.D. AP. Interaction between Jak/Stat3 and ROS generation in pancreatic cancer; 2011 Nov. (Advances in cell signaling, Cancer prevention and therapeutics Annual Meeting, South Padre Island, Tx).
|
| Batth IS, Weintraub ST, Kumar, Ph.D. AP. 2-Methoxyestradiol targets RON kinase and FLIP to inhibit epithelial-mesenchymal transition in Prostate Cancer; 2011 Nov. (Advances in Cell Signaling, Cancer Prevention).
|
| Xie, J., Rivas, P., Soundararajan, A., David, M.D., Yeh, I-T., Ghosh, R and Kumar, A.P. Interactions among transcription factors as a potential mechanism for inhibiting castrate-resistant prostate cancer (CRPCa) in transgenic adenocarcinoma of mouse prostate (TRAMP) through regulation of FLIP; 2011 Apr. (102ND Annual meeting of the American Association for Cancer Research).
|
| Xie, J., Ghosh, R. and Kumar, A.P. 2-Methoxyestradiol (2-ME2) induces microRNA alterations in prostate cancer cells: Role for miRs in 2-ME2-induced biological effects; 2011 Apr. (102ND Annual meeting of the American Association for Cancer Research).
|
| Gong J, Batth IS, Kumar, Ph.D. AP. Jak/STAT3 signaling: A potential target for pancreatic cancer management; 2011 Apr. (American Associaton for Cancer Research 102 nd Annual Meeting, Orlando, FL).
|
| Gong, J., Batth, I.S. and Kumar, A.P. Jak/Stat signaling: a potential target for pancreatic cancer management; 2011 Apr. (102ND Annual meeting of the American Association for Cancer Research).
|
| Kumar, A.P., Swanson, G.P., Thompson, I.M. and Ghosh, R. Molecular targeted approaches for cancer management; 2011 Jan. (Invited presentation at Plenary session at 98th Indian Science Congress January 2011).
|
| A. Gupta, M. Mann, A.P. Kumar, B.O. Oyajobi. Anti-tumor effect of Nextrutine, a Phellodendron amurense Bark Extract; 2011 Jan. (102ND Annual meeting of the American Association for Cancer Research, April 2011).
|
| Gong, J., Freeman, J.W. and Kumar, A.P. NFkB and Stat3 interaction: a potential target for pancreatic cancer management; 2010 Nov. (12TH Annual South Padre Island Symposium on Advances in Cell signaling cancer prevention and Cancer Therapy).
|
| Jingjing Gong, James W Freeman and Kumar, Ph.D. AP. NF-kappaB and Stat3 interaction: a potential target for pancreatic cancer management; 2010 Nov. (Advances in cell signaling, Cancer prevention and therapeutics Annual Meeting, South Padre Island, Tx).
|
Review Article |
| SS Hussain, APKumar and R Ghosh. Food based natural products for cancer management: Is the whole greater than the sum of the parts? Seminars in Cancer Biology 2016 Aug;.
|
| Hussain, SS., Patel, D., Ghosh, R and Kumar AP. Extracting the Benefit of Nexrutine for Cancer Prevention Curr Pharmacol Rep 2015 Dec;:365-372.
|
| Kumar AP. Recepteur d''origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer Molecular Carcinogenesis 2015 Oct;.
|
| Mukherjee,N., Kumar AP and Ghosh R. DNA Methylation and Flavonoids in Genitourinary Cancers Curr Pharmacol Rep 2015 Apr;:112-120.
|
| Gong, JJ., Kumar,S., Graham, G, and Kumar, AP. FLIP: Molecular switch between apoptosis and necroptosis Molecular Carcinogenesis (in perspective, DOI 10.1002/MC.22027) 2013 Jan;.
|
| Kumar, Ph.D. AP. FLIP MOLECULAR SWITCH BETWEEN APOPTOSIS AND NECROPTOSIS Molecular Carcinogenesis 2013 Jan;.
|
